Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Hepatol. Jan 28, 2017; 9(3): 139-146
Published online Jan 28, 2017. doi: 10.4254/wjh.v9.i3.139
Table 1 Baseline characteristics comparing non-alcoholic steatohepatitis recipients to all other etiologies of liver disease n (%)
NASH (n = 3240)Other etiologies (n = 31832)P value
Recipient characteristics
Age at listing, mean years (95%CI)57.6 (57.3-57.9)52.2 (52.1-52.3)< 0.001
Age at transplant, mean years (95%CI)58.1 (57.8-58.4)52.7 (52.6-52.8)< 0.001
Male gender1747 (52.9)22099 (67.3)< 0.001
African American race65 (2.0)3.559 (10.9)< 0.001
Hispanic race348 (10.5)4009 (12.2)0.005
BMI at transplant, kg/m2, mean (95%CI)32.3 (32.0-32.5)27.8 (27.7-27.9)< 0.001
Hypertension requiring medical treatment160 (33.2)2155 (19.2)< 0.001
Diabetes1698 (51.4)6211 (18.9)< 0.001
Portal vein thrombosis394 (12.2)2232 (7.1)< 0.001
Etiology of liver disease
Alcohol alone6236 (19.0)
Autoimmune disease1.202 (3.7)
Cholestatic disease3638 (11.1)
Hepatitis B986 (3.0)
Hepatitis C15298 (46.6)
Other4472 (14.0)
Severity of liver disease
MELD score at listing, mean (95%CI)20.0 (19.8-20.3)19.6 (19.5-19.7)0.014
MELD score at transplantation, mean (95%CI)23.5 (23.2-23.8)22.8 (22.7-22.9)< 0.001
Laboratory values
Serum bilirubin, mg/dL, mean (95%CI)7.4 (7.1-7.8)9.1 (9.0-9.2)< 0.001
INR, mean (95%CI)1.92 (1.90-1.95)1.93 (1.92-1.94)NS
Serum albumin, g/dL, mean (95%CI)3.0 (3.0-3.1)3.0 (2.9-3.0)0.002
Creatinine, g/dL, mean (95%CI)1.81 (1.76-1.86)1.65 (1.63-1.67)< 0.001
On dialysis at transplantation488 (10.6)4135 (12.2)< 0.001
Portal hypertension manifestations
Moderate-severe ascites at transplant1210 (36.7)10782 (32.9)< 0.001
Moderate-severe hepatic encephalopathy at transplant375 (11.7)3708 (11.3)NS
Table 2 Baseline characteristics comparing high-risk non-alcoholic steatohepatitis to low-risk non-alcoholic steatohepatitis recipients
High-risk NASH (n = 465)Low-risk NASH (n = 2775)P value
Recipient characteristics
Age at listing, mean years (95%CI)64.0 (63.8-64.3)56.7 (56.2-56.9)< 0.001
Age at transplant, mean years (95%CI)64.5 (64.2-64.7)57.0 (56.8-57.4)< 0.001
Male gender247 (52.4)1500 (53.0)NS
African American race7 (0.2)58 (1.6)NS
Hispanic race43 (9.1)305 (10.8)NS
BMI at transplant, kg/m2, mean (95%CI)35.1 (34.7-35.5)31.8 (31.5-32.0)< 0.001
Portal vein thrombosis66 (14.2)326 (11.8)NS
Severity of liver disease
MELD score at listing, mean (95%CI)19.5 (18.7-20.3)20.1 (19.8-20.4)NS
MELD score at transplantation, mean (95%CI)22.8 (21.9-23.6)23.7 (23.3-24.0)NS
Laboratory values
Serum bilirubin, mg/dL, mean (95%CI)6.2 (5.4-7.0)7.7 (7.3-8.0)0.002
INR, mean (95%CI)1.81 (1.75-1.86)1.94 (1.91-1.97)0.002
Serum albumin, g/dL, mean (95%CI)3.1 (3.0-3.2)3.0 (2.9-3.1)0.006
Creatinine, g/dL, mean (95%CI)1.98 (1.85-2.11)1.78 (1.73-1.83)0.003
On dialysis at transplantation73 (15.5)415 (14.7)NS
Portal hypertension manifestations
Moderate-severe ascites at transplant178 (37.8)1032 (36.5)NS
Moderate-severe hepatic encephalopathy at transplant51 (10.8)324 (11.5)NS
Table 3 Adjusted multivariable analysis for predictors of portal vein thrombosis at the time of liver transplantation
Odds ratio95%CIP value
African American race0.750.64-0.89< 0.001
AIH1.431.14-1.790.002
Hispanic race1.241.10-1.39< 0.001
HR-NASH2.111.60-2.76< 0.001
LR-NASH1.711.49-1.96< 0.001
Male gender1.181.07-1.29< 0.001
Moderate-severe ascites1.141.04-1.250.007